Presentation is loading. Please wait.

Presentation is loading. Please wait.

High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.

Published byRudolf Tóth Modified over 5 years ago

Similar presentations

Presentation on theme: "High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput."— Presentation transcript:

1 High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. A, Pie chart of 112 drugs: color code corresponds to hit target type. B, Top hits identified across 112 drugs tested in combination with ARS1620. Only combinations yielding at least 1 instance of a 5-fold shift in IC50 in the presence of ARS1620 over single agent are presented. C, Pattern of a selected panel of recurrent effective combination across cell lines. IC50 shift (median across biological replicates) is shown. Sandra Misale et al. Clin Cancer Res 2019;25: ©2019 by American Association for Cancer Research

Download ppt "High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput."

Similar presentations

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Modulation of KRASG12C activity alters ARS-853 target engagement and supports novel therapeutic strategies for targeting KRAS. A, schematic for altering.

Modulation of KRASG12C activity alters ARS-853 target engagement and supports novel therapeutic strategies for targeting KRAS. A, schematic for altering.
Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 4 Possible combination therapies CDK4/6 inhibitors
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway
High-throughput analysis of informative CpG sites for the four studied tumor suppressor genes (A-D). High-throughput analysis of informative CpG sites.

High-throughput analysis of informative CpG sites for the four studied tumor suppressor genes (A-D). High-throughput analysis of informative CpG sites.
AKT dependence of ovarian cancer cell lines.

AKT dependence of ovarian cancer cell lines.
ASSIGNMENT 10 Use the UP and DOWN tags as provided and query the LINCS. These are the KRAS-DEP (UP) and KRAS-IND (DOWN) gene signatures from Singh et al.

ASSIGNMENT 10 Use the UP and DOWN tags as provided and query the LINCS. These are the KRAS-DEP (UP) and KRAS-IND (DOWN) gene signatures from Singh et al.
IL32 prompts cell activation and cancer-related pathways.

IL32 prompts cell activation and cancer-related pathways.
High-throughput combination drug screening to nominate potent drug combinations. High-throughput combination drug screening to nominate potent drug combinations.

High-throughput combination drug screening to nominate potent drug combinations. High-throughput combination drug screening to nominate potent drug combinations.
Genetic landscape of salivary duct carcinoma.

Genetic landscape of salivary duct carcinoma.
K-Means clustering of protein and mRNA expression patterns after PPAR agonists treatments. k-Means clustering of protein and mRNA expression patterns after.

K-Means clustering of protein and mRNA expression patterns after PPAR agonists treatments. k-Means clustering of protein and mRNA expression patterns after.
A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.
Reproducibility of DeathPro drug screens

Reproducibility of DeathPro drug screens
Predicting drug sensitivity from proteomic (RPPA) data clusters.

Predicting drug sensitivity from proteomic (RPPA) data clusters.
CD16 uses additional pathways for killing.

CD16 uses additional pathways for killing.
NAPRT expression correlates to sensitivity for NAMPT inhibitors and to methylation of the CpG island of the NAPRT promoter. NAPRT expression correlates.

NAPRT expression correlates to sensitivity for NAMPT inhibitors and to methylation of the CpG island of the NAPRT promoter. NAPRT expression correlates.
Derivation of ImSig. Derivation of ImSig. A, An example of a correlation network generated from a tissue data set where nodes represent unique genes and.

Derivation of ImSig. Derivation of ImSig. A, An example of a correlation network generated from a tissue data set where nodes represent unique genes and.
Sensitivity analysis of cellular responses to perturbation of the DNA damage response signaling in the presence of chemotherapies. Sensitivity analysis.

Sensitivity analysis of cellular responses to perturbation of the DNA damage response signaling in the presence of chemotherapies. Sensitivity analysis.
Table A and B, in vitro synergy of romidepsin and pralatrexate (PDX) in TCL cell lines. Table A and B, in vitro synergy of romidepsin and pralatrexate.

Table A and B, in vitro synergy of romidepsin and pralatrexate (PDX) in TCL cell lines. Table A and B, in vitro synergy of romidepsin and pralatrexate.
SiRNA screening identifies genes required for the viability of Pim1-ovexpressing prostate cells. siRNA screening identifies genes required for the viability.

SiRNA screening identifies genes required for the viability of Pim1-ovexpressing prostate cells. siRNA screening identifies genes required for the viability.

Similar presentations

Ads by Google